Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
[ad_1]
Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout.
[ad_2]
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/T25U7SQSSZMCBKWS45FYE6XFKU.jpg){kind=small}